# Amgen Inc. (AMGN) FY2024 Q3 P&L / Income Statement

- Company: Amgen Inc. (AMGN)
- Period: 2024-07-01 to 2024-09-30
- Filing: Q3 FY2024 10-Q, filed 2024-10-31, accession number 0000318154-24-000044
- Page: https://plicit.ai/financials/amgn/fy2024-q3-income-statement
- Chart image: https://plicit.ai/charts/amgn-fy2024-q3-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2024-07-01 through 2024-09-30. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 8,503,000,000 US dollars
- **Cost of sales**: 3,310,000,000 US dollars
- **Gross profit (calculated)**: 5,193,000,000 US dollars
- **Operating expenses (calculated)**: 3,146,000,000 US dollars
- **Operating income**: 2,047,000,000 US dollars
- **Other income (expense), net (calculated)**: 1,054,000,000 US dollars
- **Income before income taxes**: 3,101,000,000 US dollars
- **Provision for income taxes**: 271,000,000 US dollars
- **Net income**: 2,830,000,000 US dollars
- **Aranesp - UNITED STATES**: 105,000,000 US dollars
- **Aranesp - Non-US**: 232,000,000 US dollars
- **BLINCYTO - UNITED STATES**: 237,000,000 US dollars
- **BLINCYTO - Non-US**: 90,000,000 US dollars
- **EVENITY - UNITED STATES**: 289,000,000 US dollars
- **EVENITY - Non-US**: 110,000,000 US dollars
- **ENBREL - UNITED STATES**: 817,000,000 US dollars
- **ENBREL - Non-US**: 8,000,000 US dollars
- **KRYSTEXXA - UNITED STATES**: 310,000,000 US dollars
- **KRYSTEXXA - Non-US**: 0 US dollars
- **Kyprolis - UNITED STATES**: 238,000,000 US dollars
- **Kyprolis - Non-US**: 140,000,000 US dollars
- **Nplate - UNITED STATES**: 345,000,000 US dollars
- **Nplate - Non-US**: 111,000,000 US dollars
- **Otezla - UNITED STATES**: 460,000,000 US dollars
- **Otezla - Non-US**: 104,000,000 US dollars
- **Other products - UNITED STATES**: 958,000,000 US dollars
- **Other products - Non-US**: 405,000,000 US dollars
- **Prolia - UNITED STATES**: 683,000,000 US dollars
- **Prolia - Non-US**: 362,000,000 US dollars
- **Repatha - UNITED STATES**: 281,000,000 US dollars
- **Repatha - Non-US**: 286,000,000 US dollars
- **TEPEZZA - UNITED STATES**: 482,000,000 US dollars
- **TEPEZZA - Non-US**: 6,000,000 US dollars
- **TEZSPIRE - UNITED STATES**: 269,000,000 US dollars
- **TEZSPIRE - Non-US**: 0 US dollars
- **Vectibix - UNITED STATES**: 132,000,000 US dollars
- **Vectibix - Non-US**: 150,000,000 US dollars
- **XGEVA - UNITED STATES**: 373,000,000 US dollars
- **XGEVA - Non-US**: 168,000,000 US dollars
- **Product sales - UNITED STATES**: 5,979,000,000 US dollars
- **Product sales - Non-US**: 2,172,000,000 US dollars
- **Research and development**: 1,450,000,000 US dollars
- **Selling, general and administrative**: 1,625,000,000 US dollars
- **Other**: 71,000,000 US dollars
- **Revenue before reconciliation (calculated)**: 16,302,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- **Components above reported revenue (calculated)**: negative 7,799,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.

## Chart details: Revenue by Product and Service (16 categories)

- Page: https://plicit.ai/financials/amgn/fy2024-q3-income-statement/revenue-by-product-and-service-16-categories
- Chart image: https://plicit.ai/charts/amgn-fy2024-q3-revenue-by-product-and-service-16-categories-sankey.png

Income statement for 2024-07-01 through 2024-09-30. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 8,503,000,000 US dollars
- **Cost of sales**: 3,310,000,000 US dollars
- **Gross profit (calculated)**: 5,193,000,000 US dollars
- **Operating expenses (calculated)**: 3,146,000,000 US dollars
- **Operating income**: 2,047,000,000 US dollars
- **Other income (expense), net (calculated)**: 1,054,000,000 US dollars
- **Income before income taxes**: 3,101,000,000 US dollars
- **Provision for income taxes**: 271,000,000 US dollars
- **Net income**: 2,830,000,000 US dollars
- **Prolia**: 1,045,000,000 US dollars
- **ENBREL**: 825,000,000 US dollars
- **XGEVA**: 541,000,000 US dollars
- **Repatha**: 567,000,000 US dollars
- **Otezla**: 564,000,000 US dollars
- **TEPEZZA**: 488,000,000 US dollars
- **EVENITY**: 399,000,000 US dollars
- **Kyprolis**: 378,000,000 US dollars
- **Nplate**: 456,000,000 US dollars
- **Aranesp**: 337,000,000 US dollars
- **KRYSTEXXA**: 310,000,000 US dollars
- **BLINCYTO**: 327,000,000 US dollars
- **Vectibix**: 282,000,000 US dollars
- **TEZSPIRE**: 269,000,000 US dollars
- **Other products**: 1,363,000,000 US dollars
- **Other revenues**: 352,000,000 US dollars
- **Research and development**: 1,450,000,000 US dollars
- **Selling, general and administrative**: 1,625,000,000 US dollars
- **Other**: 71,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (2 categories)

- Page: https://plicit.ai/financials/amgn/fy2024-q3-income-statement/revenue-by-product-and-service-2-categories
- Chart image: https://plicit.ai/charts/amgn-fy2024-q3-revenue-by-product-and-service-2-categories-sankey.png

Income statement for 2024-07-01 through 2024-09-30. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 8,503,000,000 US dollars
- **Cost of sales**: 3,310,000,000 US dollars
- **Gross profit (calculated)**: 5,193,000,000 US dollars
- **Operating expenses (calculated)**: 3,146,000,000 US dollars
- **Operating income**: 2,047,000,000 US dollars
- **Other income (expense), net (calculated)**: 1,054,000,000 US dollars
- **Income before income taxes**: 3,101,000,000 US dollars
- **Provision for income taxes**: 271,000,000 US dollars
- **Net income**: 2,830,000,000 US dollars
- **Product sales**: 8,151,000,000 US dollars
- **Other revenues**: 352,000,000 US dollars
- **Research and development**: 1,450,000,000 US dollars
- **Selling, general and administrative**: 1,625,000,000 US dollars
- **Other**: 71,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.